晚期乳癌電子報分類文章　顯示方式：簡文 | 列表

2009年07月29日

晚期乳癌電子報 第 217 期

Vinflunine：晚期乳癌之新的第二線治療藥物
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy
British Journal of Cancer (2006) 95, 1161-1166. ...繼續閱讀

Posted by jaymyang at 樂多Roodo!│ 20:57 │ 回應(0) │ 引用(0)

晚期乳癌電子報第 216 期

在經過多種治療的轉移乳癌病人併用健澤與oxaliplatin
Gemcitabine–Oxaliplatin Combination in Heavily Pretreated Metastatic Breast Cancer: A Pilot Study on 43 Patients
Volume 13 Issue 2 Page 165 - March/April 2007 ...繼續閱讀

Posted by jaymyang at 樂多Roodo!│ 20:55 │ 回應(0) │ 引用(0)

晚期乳癌電子報 第 215 期

Capecitabine
The Oncologist, Vol. 12, No. 2, 152-155, February 2007;
doi:10.1634/theoncologist.12-2-152
Schellens, J. H.M. ...繼續閱讀

Posted by jaymyang at 樂多Roodo!│ 20:51 │ 回應(0) │ 引用(0)

晚期乳癌電子報 第 214 期

1.
不管先前是否接受過雙磷酸鹽類藥物治療，ibandronate都可以減低病人的疼痛
[1076] Pain reduction with ibandronate is achieved regardless of prior bisphosphonate treatment.

2.
以15分或60分之時間經靜脈注射ibandronate對於腎臟的安全性
[1078] Renal safety of intravenous ibandronate 6mg infused over 15 or 60 minutes in patients with breast cancer and bone metastases. ...繼續閱讀

Posted by jaymyang at 樂多Roodo!│ 20:47 │ 回應(0) │ 引用(0)

晚期乳癌電子報 第 213 期

1.
併用Iressa與docetaxel治療轉移乳癌病人
[1093] A randomized phase II trial with gefitinib and docetaxel in metastatic breast cancer: an evaluation of the treatment regimen and the factors associated with toxicity.
2.
併用Avastin以及與白蛋白結合之紫杉醇（Abraxane）治療轉移乳癌病人
[1095] Bevacizumab (avastin) and albumin bound paclitaxel (abraxane) treatment in metastatic breast cancer. ...繼續閱讀

Posted by jaymyang at 樂多Roodo!│ 20:44 │ 回應(0) │ 引用(0)

晚期乳癌電子報 第 212 期

1.
以lapatinib作為罹患過度表現ErbB2之晚期或轉移乳癌併的第一線治療
[1090] Updated biomarker results from a phase II randomized study of lapatinib as first-line treatment for patients with ErbB2-amplified advanced or metastatic breast cancer.

2.
Lapatinib治療晚期或轉移乳癌病人的第二期試驗
[1091] Phase II clinical study of lapatinib (GW572016) in patients with advanced
or metastatic breast cancer. ...繼續閱讀

Posted by jaymyang at 樂多Roodo!│ 20:41 │ 回應(0) │ 引用(0)

晚期乳癌電子報 第 211 期

1.
併用截瘤達與Avastin作為轉移乳癌病人第一線治療
[2068] Capecitabine plus bevacizumab in first line metastatic breast cancer: an interim safety and efficacy report of the first phase of xeloda plus avastin 1st line metastatic breast cancer trial.
2.
使用正子造影掃描評估罹患HER2陽性之轉移乳癌病人以lapatinib治療的效果
[1089] Evaluation of response to lapatinib in patients with HER2-positive metastatic breast cancer using FDG-PET. ...繼續閱讀

Posted by jaymyang at 樂多Roodo!│ 20:39 │ 回應(0) │ 引用(0)

晚期乳癌電子報 第 210 期

1.
Herceptin 與 KOS-953治療Her2陽性乳癌病人
[1102] Phase 2 trial of trastuzumab (T) and KOS-953 (17-AAG) in patients with Her2-positive breast cancer: preliminary results.
2.
截瘤達與vinnorelbine在罹患轉移乳癌的老年病人作為第一線治療：第二期試驗
[6089] Capecitabine (C) and vinorelbine (V) in elderly patients (pts.) with metastatic breast cancer (MBC) as 1st line treatment: a prospective multicentre phase II study of the NOGGO breast cancer study group. ...繼續閱讀

Posted by jaymyang at 樂多Roodo!│ 20:34 │ 回應(0) │ 引用(0)

晚期乳癌電子報 第 206-209 期

Lapatinib在乳癌治療的現況與未來展望
Lapatinib: Current Status and Future Directions in Breast Cancer
Beverly Moy, Paul E. Goss
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
The Oncologist, Vol. 11, No. 10, 1047-1057, November 2006 ...繼續閱讀

Posted by jaymyang at 樂多Roodo!│ 20:27 │ 回應(0) │ 引用(0)

2009年07月27日

晚期乳癌電子報 第 203-205 期

賀癌平抗藥性的分子機轉
Molecular Mechanisms of trastuzumab Resistance
Breast Cancer Research 2006,8:215 ...繼續閱讀

Posted by jaymyang at 樂多Roodo!│ 20:46 │ 回應(0) │ 引用(0)
 [第一頁]  [1]  [2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  [10]  [下10頁]  [最終頁] 
回頁首▲